National Institutes of Health: Malignant Carcinoid Syndrome trials
The registry lists 12 Malignant Carcinoid Syndrome studies with National Institutes of Health as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 4Phase 2 6No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
- Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
- Temsirolimus in Treating Patients With Metastatic Neuroendocrine CarcinomaCompletedNCT00093782Phase 2Results posted
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
- Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine TumorsStatus unknownNCT00454376
- Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
- EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
- Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsTerminatedNCT00084461Phase 2
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00075439Phase 2
- Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid TumorsCompletedNCT00055809Phase 2
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
- Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1